Please login to the form below
Hypertrophic cardiomyopathy
This page shows the latest Hypertrophic cardiomyopathy news and features for those working in and with pharma, biotech and healthcare.
Bristol Myers Squibb’s Camzyos recommended by NICE for inherited heart condition
One in 500 people in the UK are affected by hypertrophic cardiomyopathy. ... eligible. Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition and affects around one in 500 people in the UK.
Latest news
-
Cytokinetics to discontinue ALS drug candidate following phase 3 trial failure
development for patients with obstructive hypertrophic cardiomyopathy.
-
SOLVE FSHD announces the appointment of Dr Eva Chin as its executive director
SMA), myasthenia gravis and hypertrophic cardiomyopathy.
-
BMS builds case for cardiovascular drug mavacamten with new analysis
Bristol Myers Squibb has reported some new analysis for its investigational cardiovascular drug mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a chronic and progressive disease which
-
FDA accepts BMS’ investigational cardiovascular drug mavacamten for review
The US Food and Drug Administration (FDA) is set to review Bristol Myers Squibb’s (BMS) investigational candidate mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). ... Hypertrophic cardiomyopathy (HCM) is a
-
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
As part of the merger, BMS has now gained the rights to MyoKardia’s investigational treatment mavacamten, which is currently in development for obstructive hypertrophic cardiomyopathy (HCM).
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
For a registry study, Novartis asked patients to complete the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which tracks physical limitations, symptom frequency, social limitation and quality of life. ... MyoKardia is gathering PROs in its
-
Pharma deals during September 2014
Myokardia will develop two HCM (hypertrophic cardiomyopathy) programmes where it retains US commercialisation rights and Sanofi has ex-US rights; and a third DCM (dilated cardiomyopathy) programme will be developed by
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Jonathan Fox leaves AstraZeneca for MyoKardia
MyoKardia's genetically targeted approach and cutting-edge platform has the potential to fundamentally change the lives of patients with hypertrophic cardiomyopathy and dilated cardiomyopathy,” he said.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Wallace Health
Wallace Health is a healthcare and medical content agency with a successful track record of delivering web content, content marketing...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
